



## **Supporting Information**

### **Supplementary methods and results**

**This appendix was part of the submitted manuscript and has been peer reviewed.  
It is posted as supplied by the authors.**

Appendix to: Hettipathirana T, Macdonald C, Xie J, et al. The value of clinical breast examination in a breast cancer surveillance program for women with germline *BRCA1* or *BRCA2* mutations. *Med J Aust* 2021; doi: 10.5694/mja2.51226.

**Figure. Risk Management Clinic visit note template, from which information on clinical breast examinations was extracted**

Dear Dr

<b>Surname:</b>
<b>Given Names:</b>
<b>URN:</b>
<b>DOB:</b>

Your patient \_\_\_\_\_ was seen for follow up at the Peter MacCallum Cancer Centre Breast/Ovarian Risk Management Clinic on \_\_\_\_\_ .

The following examinations/tests were performed:

- |  |  |
|--|--|
| <input type="checkbox"/> Clinical breast examination | <input type="checkbox"/> Normal                                    |
|  | <input type="checkbox"/> Abnormal, requiring further investigation |
| <br>   |  |
| <input type="checkbox"/> Mammogram                   | <input type="checkbox"/> Normal                                    |
|  | <input type="checkbox"/> Abnormal, requiring further investigation |
| <br>   |  |
| <input type="checkbox"/> MRI                         | <input type="checkbox"/> Normal                                    |
|  | <input type="checkbox"/> Abnormal, requiring further investigation |

Other Comments :

Her next appointment at the clinic is on \_\_\_\_\_.

Yours sincerely

**Table. Characteristics of the 35 women in our study diagnosed with breast cancer**

Patient	Age (years)	Screening modality				Histology	Size (mm)	Nodal status*
		Breast examination	Mammography	MRI	Ultrasound			
1	50	-	+	+	NP	IDC	5	0
2	73	-	+	NP	NP	IDC	9	NP
3†	34	-	-	-	NP	IDC	18	0
4	36	-	-	+	NP	IDC	5	0
5	49	-	-	+	NP	DCIS	9	0
6	31	-	NP	+	NP	IDC	9	1
7	36	+	-	NP	-	IDC	24	4
8	52	-	-	+	NP	IDC	15	0
9	45	-	-	+	NP	IDC	8	0
10	48	-	-	+	NP	DCIS	25	NP
11	62	-	+	NP	NP	DCIS	25	NP
12	35	-	-	+	NP	DCIS	30	NP
13	37	-	-	+	NP	DCIS	6	0
14	39	-	-	+	NP	IDC	15	0
15	44	-	-	+	-	IDC	11	0
16	34	-	+	-	NP	DCIS	4	NP
17	51	+	+	-	NP	IDC	8	0
18	48	-	-	+	NP	IDC	8	0
19	25	-	NP	+	NP	DCIS	14	0
20†	37	-	-	-	NP	IDC	22	0
21†	38	-	-	-	-	IDC	25	0
22†	30	-	-	-	NP	IDC	15	0
23	44	-	+	+	NP	DCIS	20	0
24	30	-	-	+	NP	IDC	15	2
25	35	-	-	+	NP	IDC	8	0
26	65	+	-	NP	-	ILC	22	0
27	33	-	-	+	-	DCIS	47	0
28†	56	-	-	-	-	Unknown	26	1
29	28	-	-	+	NP	DCIS	1	0
30†	33	-	-	+	NP	DCIS	35	0
31	40	-	-	+	NP	DCIS	11	NP
32†	35	-	-	-	NP	IDC	20	0
33†	33	-	-	-	NP	Unknown	Unknown	Unknown
34	43	-	-	+	-	DCIS	1	NP
35	24	-	NP	+	NP	IDC	Unknown	NP

Screening Results: +, abnormal; -, normal; NP, not performed.

DCIS = ductal carcinoma in situ; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; MRI = magnetic resonance imaging.

\* Number of axillary positive nodes.

† Interval cancer.